趋势:PayScale and Payfactors combine into 600-person company, eyeing big market for compensation data
缺口治疗方法是在Juan-CarlosZúñiga-pflücker实验室中开发的商业化技术,左侧,陷波的科学咨询委员会,以及首席科学官Peter Zandstra。(多伦多大学和Notch照片)

New funding:Notch Therapeutics已经筹集了8500万美元的一轮,使其总额为9100万美元。Biotech公司成立于2018年,正在开发干细胞衍生的癌症免疫治疗。

西雅图扩建:The startup has offices in Vancouver, B.C. and Toronto and will use some of the new capital to open a facility in Seattle, adding another player to the city’s growing biotech scene. Notch currently has 35 employees, with plans to grow that number to 100 by the end of 2022. About 20 of those jobs will be in Seattle, where it is opening a research laboratory, with the possibility of expanding into regulatory and clinical functions.

生物技术创新:该公司正在开发一个生物技术平台,可以采取可再生干细胞系,并操纵其开发,使其成为疗法中使用的T细胞和其他类型的免疫细胞。该公司的工程胸腺利基平台如此命名,因为它模仿人类胸腺的动作,导致细胞区分为专用细胞类型。

加州的命运治疗方法等公司也正在从类似种类的干细胞开发T细胞,但诺茨官员表示,由于其在不使用单独的饲养细胞系或动物试剂的情况下控制T细胞发育的能力,他们的技术是特殊的。

该启动是用异种治疗学合作,为非霍奇金淋巴瘤,白血病和多发性骨髓瘤进行治疗。

David Main, Notch Therapeutics president and CEO. (Notch Photo)

创始人的章程:Notch Therapeutics is commercializing technologies developed in the labs of胡安•卡洛斯Zuniga-Pflucker,陷波科学咨询委员会主席,以及首席科学官Peter Zandstra。除了他与缺口的角色外,Zúñiga-Pflücker是桑尼布鲁克研究所和多伦多大学卫士椅的研究员。Zandstra是英国哥伦比亚大学和多伦多大学的教授,是卓越的卓越的联合创始人,并是再生医学的商业化的中心。

David Mainis Notch president and CEO. He co-founded Aquinox Pharmaceuticals.

Immunotherapy hotbed:西雅图是众多机构开发免疫治疗治疗的家园。包括弗雷德·哈钦森癌症研究中心和西雅图癌症关怀联盟,也是贝萨斯家庭免疫疗法诊所的共同回家,以及贝纳罗摩研究所和西雅图儿童医院。

Local immunotherapy biotech companies include Umoja Biopharma, Sana Biotechnology, Chinook Therapeutics, Kineta, Alpine Immune Sciences, Adaptive Biotechnologies, and others.

Investor interest:The financing was led by an unnamed healthcare-focused investment fund, with participation by existing investors Allogene Therapeutics, Lumira Ventures and CCRM Enterprises Holdings, as well as new investors EcoR1 Capital, Casdin Capital, Samsara BioCapital, Amplitude Ventures and an undisclosed firm.

“We have great confidence in Notch’s high-caliber management team and the rigorous science underlying its research programs,” said Dr. David Chang, president and CEO of Allogene and member of the Notch board of directors.

喜欢你在读什么?订阅Geekwire的免费新闻通讯以捕捉每个标题

Geekwork上的工作列表

找到更多的工作Geekwork.。Employers,岗位